Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
NCT02817945
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Neuroendocrine Neoplasm
Interventions
DRUG:
68Ga-NOTA-3P-TATE-RGD
Sponsor
Peking Union Medical College Hospital